387 related articles for article (PubMed ID: 32378070)
1. Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study.
Kiltz U; Sfikakis PP; Gaffney K; Sator PG; von Kiedrowski R; Bounas A; Gullick N; Conrad C; Rigopoulos D; Lespessailles E; Romanelli M; Ghislain PD; Brandt-Jürgens J; Rashkov R; Aassi M; Orsenigo R; Perella C; Pournara E; Gathmann S; Jagiello P; Veit J; Augustin M
Adv Ther; 2020 Jun; 37(6):2865-2883. PubMed ID: 32378070
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
Deodhar A; Mease PJ; McInnes IB; Baraliakos X; Reich K; Blauvelt A; Leonardi C; Porter B; Das Gupta A; Widmer A; Pricop L; Fox T
Arthritis Res Ther; 2019 May; 21(1):111. PubMed ID: 31046809
[TBL] [Abstract][Full Text] [Related]
3. Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study.
Augustin M; Sator PG; von Kiedrowski R; Conrad C; Rigopoulos D; Romanelli M; Ghislain PD; Torres T; Ioannides D; Aassi M; Schulz B; Jagiello P;
J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1796-1804. PubMed ID: 35696305
[TBL] [Abstract][Full Text] [Related]
4. Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis.
Elewski BE; Baddley JW; Deodhar AA; Magrey M; Rich PA; Soriano ER; Soung J; Bao W; Keininger D; Marfo K; Patekar M; Sharma A; Shete A; Lebwohl MG
JAMA Dermatol; 2021 Jan; 157(1):43-51. PubMed ID: 33001147
[TBL] [Abstract][Full Text] [Related]
5. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.
Schreiber S; Colombel JF; Feagan BG; Reich K; Deodhar AA; McInnes IB; Porter B; Das Gupta A; Pricop L; Fox T
Ann Rheum Dis; 2019 Apr; 78(4):473-479. PubMed ID: 30674475
[TBL] [Abstract][Full Text] [Related]
6. Pharmaco-utilization of biologic drugs in patients affected by psoriasis, psoriatic arthritis and ankylosing spondylitis in an Italian real-world setting.
Zagni E; Colombo D; Fiocchi M; Perrone V; Sangiorgi D; Andretta M; De Sarro G; Nava E; Degli Esposti L
Expert Rev Pharmacoecon Outcomes Res; 2020 Oct; 20(5):491-497. PubMed ID: 32701033
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease.
Reich K; Warren RB; Coates LC; Di Comite G
J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1161-1173. PubMed ID: 31785165
[TBL] [Abstract][Full Text] [Related]
8. Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab.
Kiltz U; Sfikakis PP; Gaffney K; Bounas A; Gullick N; Lespessailles E; Brandt-Juergens J; Rashkov R; Schulz B; Pournara E; Jagiello P
Rheumatol Ther; 2022 Aug; 9(4):1129-1142. PubMed ID: 35674938
[TBL] [Abstract][Full Text] [Related]
9. Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
Gottlieb AB; Deodhar A; Mcinnes IB; Baraliakos X; Reich K; Schreiber S; Bao W; Marfo K; Richards HB; Pricop L; Shete A; Trivedi V; Keefe D; Papavassilis CC; Jagiello P; Papanastasiou P; Mease PJ; Lebwohl M
Acta Derm Venereol; 2022 Apr; 102():adv00698. PubMed ID: 35146532
[TBL] [Abstract][Full Text] [Related]
10. The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up.
Lebwohl M; Deodhar A; Griffiths CEM; Menter MA; Poddubnyy D; Bao W; Jehl V; Marfo K; Primatesta P; Shete A; Trivedi V; Mease PJ
Br J Dermatol; 2021 Nov; 185(5):935-944. PubMed ID: 33829482
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.
Deodhar A; Blauvelt A; Lebwohl M; Feely M; Kronbergs A; Eberhart N; Zhu D; Inman E; Grace E; Holzkaemper T; Rahman P; Marzo-Ortega H; Papp KA; Merola JF; Gottlieb AB; Schwartzman S
Arthritis Res Ther; 2024 Feb; 26(1):49. PubMed ID: 38347650
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab Drug Survival in Psoriasis and Psoriatic Arthritis Patients: A 24-Month Real-Life Study.
Ortolan A; Lorenzin M; Leo G; Pampaloni F; Messina F; Doria A; Piaserico S; Ramonda R
Dermatology; 2022; 238(5):897-903. PubMed ID: 35263743
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of secukinumab in patients with psoriasis and psoriatic arthritis in a Saudi real-world setting.
Al-Homood IA; Alajlan M; Alberdisi M; Alturki M; Ahmed AA; Zakaria N
Adv Rheumatol; 2024 Apr; 64(1):34. PubMed ID: 38685124
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting.
Lynde C; Riedl E; Maul JT; Torres T; Pinter A; Fabbrocini G; Daniele F; Brnabic A; Reed C; Wilhelm S; Holzkämper T; Schuster C; Puig L
Adv Ther; 2023 Mar; 40(3):869-886. PubMed ID: 36515803
[TBL] [Abstract][Full Text] [Related]
15. Secukinumab for the treatment of psoriatic arthritis.
Baronaite Hansen R; Kavanaugh A
Expert Rev Clin Immunol; 2016 Oct; 12(10):1027-36. PubMed ID: 27550397
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab for children and adolescents with enthesitis-related arthritis and psoriatic arthritis:
Bagri NK; King H; Ramanan AV
Expert Rev Clin Immunol; 2024 May; 20(5):435-440. PubMed ID: 38186357
[TBL] [Abstract][Full Text] [Related]
17. One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study.
Chimenti MS; Fonti GL; Conigliaro P; Sunzini F; Scrivo R; Navarini L; Triggianese P; Peluso G; Scolieri P; Caccavale R; Picchianti Diamanti A; De Martino E; Salemi S; Birra D; Altobelli A; Paroli M; Bruzzese V; Laganà B; Gremese E; Conti F; Afeltra A; Perricone R
Expert Opin Biol Ther; 2020 Jul; 20(7):813-821. PubMed ID: 32401062
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort.
Molica Colella F; Zizzo G; Parrino V; Filosa MT; Cavaliere R; Fazio F; Molica Colella AB; Mazzone A
Adv Rheumatol; 2023 Mar; 63(1):15. PubMed ID: 36973825
[TBL] [Abstract][Full Text] [Related]
19. Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Conesa-Nicolás E; García-Lagunar MH; Núñez-Bracamonte S; García-Simón MS; Mira-Sirvent MC
Farm Hosp; 2020 Dec; 45(1):16-21. PubMed ID: 33443473
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.
Gottlieb AB; Merola JF; Reich K; Behrens F; Nash P; Griffiths CEM; Bao W; Pellet P; Pricop L; McInnes IB
Br J Dermatol; 2021 Dec; 185(6):1124-1134. PubMed ID: 33913511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
